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Objective:  Primary hyperparathyroidism (PHPT) is a common reason for 
referral to endocrinology but the evidence base guiding assessment is limited.  
We evaluated the clinical presentation, assessment and subsequent management 
in PHPT. 
 
Design:  Retrospective cohort study. 
 
Patients: PHPT assessed between 2006 – 2014 (n = 611) in a university hospital. 
 
Measurements:  Symptoms, clinical features, biochemistry, neck radiology and 
surgical outcomes. 
 
Results:  Fatigue (23.8%), polyuria (15.6%) and polydipsia (14.9%) were 
associated with PHPT biochemistry.  Bone fracture was present in 16.4% but 
was not associated with biochemistry.  A history of nephrolithiasis (10.0%) was 
associated only with younger age  (P = 0.006) and male gender (P = 0.037).  
Thiazide diuretic discontinuation was not associated with any subsequent 
change in calcium (P = 0.514). Urine calcium creatinine clearance ratio (CCCR) 
was <0.01 in 18.2% of patients with confirmed PHPT.  Older age (P < 0.001) and 
lower PTH (P = 0.043) were associated with failure to locate an adenoma on 
ultrasound (44.0% of scans).  When an adenoma was identified on ultrasound 
the lateralization was correct in 94.5%.  Non-curative surgery occurred in 8.2% 
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and was greater in those requiring more than one neck imaging modality (OR 
2.42, P = 0.035). 
 
Conclusions: Clinical features associated with PHPT are not strongly related to 
biochemistry.  Thiazide cessation does not appear to attenuate hypercalcaemia. 
PHPT remains the likeliest diagnosis in the presence of low CCCR.  Ultrasound is 
highly discriminant when an adenoma is identified but surgical failure is more 
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Primary hyperparathyroidism (PHPT) is a common endocrine condition with a 
prevalence of 0.1-1%, a female preponderance and a strong association with 
ageing1,2.  In the modern era, PHPT is often detected incidentally through routine 
biochemical testing and is, in this milder form, often described as asymptomatic, 
in distinction from more severe PHPT associated with classical bone, renal and 
neuropsychiatric manifestations.  Many patients with relatively modest 
hypercalcaemia will report symptoms that are potentially attributable to PHPT. 
However, the degree to which these correlate with biochemical markers of 
severity and their reversibility with surgical cure remains unclear3.  The majority 
of PHPT may remain undiagnosed as suggested by a recent study which 
identified measurement of parathyroid hormone (PTH) in only 31% of 
hypercalcaemic patients4.  In recent years the normocalcaemic variant of PHPT 
has gained increasing recognition, although this is beyond the scope of our 
investigation5. 
 
Guidance on the assessment and management of PHPT comes from the 4th 
International Workshop on PHPT. This emphasises the importance of securing 
the diagnosis of PHPT before considering whether surgical intervention is 
appropriate (a decision largely based on age, serum calcium, and presence of 
bone and/or renal complications)6.  Only when a decision to pursue surgical cure 
is made should neck imaging be performed. However the optimal imaging 
modality in this context remains unclear and in a small but important minority of 
cases, the source of PTH excess remains elusive despite multiple imaging.   The 
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international workshop recognises the value of neck imaging  by ultrasound, 
99mTc-sestamibi and CT in pre-operative localization7, but does not specify an 
optimal approach. 
 
Familial Hypocalciuric Hypercalcaemia (FHH) is an important differential 
diagnosis to exclude in patients with apparent PHPT as it is often associated with 
mild hypercalcaemia and PTH concentrations which overlap with the lower end 
of those observed in PHPT.  The initial recommended screening test to exclude 
FHH, in addition to a full family history, is the urine calcium creatinine clearance 
ratio (CCCR), which should be > 0.01 in patients with PHPT8.  Another potential 
contributor to hypercalcaemia in patients with probable PHPT is thiazide 
diuretic use, although recent reports suggest the impact to be minimal and 
paradoxically thiazides may even reduce blood PTH concentrations9.  
 
We have collated one of the largest cohorts of patients presenting for specialist 
endocrine assessment of PHPT, characterised in detail with respect to 
demographics, clinical features, biochemistry, imaging, surgery, pathology and 
subsequent outcomes.  We sought to utilise this resource to address the 
relationship between presenting features and biochemical indices of PHPT; 
assess the discriminatory value of CCCR; determine the frequency of delayed 
diagnosis of PHPT; determine factors associated with the decision to pursue 
surgery; assess the effectiveness of pre-surgical neck imaging in a ‘real world’ 
context and relate these findings to surgical outcomes.   
 
Materials and Methods 
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All patients presenting with a new diagnosis of PHPT (n = 611) to Edinburgh 
Centre for Endocrinology & Diabetes clinics (Royal Infirmary of Edinburgh & 
Western General Hospital) between 2006 and 2014 were identified from our 
comprehensive clinic database.  Patients presenting following family screening 
for genetic causes of PHPT were excluded from this cohort but all index cases 
were included. Basic demographic details were obtained from electronic patient 
records.  Social deprivation status was assessed using the ‘Scottish Index of 
Multiple Deprivation’  (SIMD 2016), which assigns individuals a rank from 1 
(most deprived) to 6976 (least deprived) based on postcode10.  Symptoms at 
presentation and other clinical features were gleaned from letters pertaining to 
PHPT in the electronic patient record.  Ethical approval for this project was not 




Calcium (plasma and urine), phosphate, magnesium, alkaline phosphatase and 
creatinine were measured by standard laboratory methods.  Adjusted calcium 
was derived using the following calculation:  [calcium] + ((40 - [albumin]) x 
0.02).  Peak calcium was defined as the highest ever recorded calcium (from data 
available 1999 – 2016). CCCR was obtained either from spot urine sample or 24 
hour urine collection, in association with contemporaneous plasma samples, 
using the following calculation:  ([urine calcium (mM)] x ([serum creatinine 
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(μM)] x 1000)) / ([serum calcium (mM)] x [urine creatinine (mM)]).  Patients 
were not on thiazide diuretics or calcium supplementation prior to urine 
collection. Three PTH assays were used across the 9 years of patient acquisition, 
all of which measured ‘intact’ 1-84 PTH: the Abbott Architect i2000 
chemiluminescent microparticle-enhanced immunoassay (50.6%), the Siemens 
Immulite 2000 solid-phase 2-site chemiluminescent enzyme linked 
immunometric assay (36.0%) and the Roche Cobas E411 
electrochemiluminescent assay (13.4%).  All reported PTH values were 
normalised to the Abbott Architect i2000 assay using regression equations (from 
locally derived comparison data).  Vitamin D was measured using LC-MS/MS; 
deficiency was defined as <25nM and insufficiency as 25 – 50nM.  Biochemical 
results dating back to 1999 were available on our system and were interrogated 
to identify the interval between a first hypercalcaemic result and the first 




The standard sequence of imaging in our centre was initial high resolution 
ultrasound with a minimum transducer frequency of 12.5MHz. 99mTc-sestamibi 
(Planar and SPECT/CT) was performed only where ultrasound failed to identify 
a source for autonomous PTH secretion or where ultrasound findings were 
equivocal.  Latterly, four-dimensional CT (4DCT) was employed where 
ultrasound and 99mTc-sestamibi-SPECT CT failed to identify an adenoma.  Results 
are presented separately for the 99mTc-sestamibi uptake component (either 
planar 99mTc-sestamibi or 99mTc-sestamibi SPECT) and the CT component of 
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concomitant 99mTc-sestamibi SPECT CT imaging.  Planar 99mTc-sestamibi and 
99mTc-sestamibi SPECT were considered as a single entity for data analysis.   In 
cases with surgically confirmed adenoma/hyperplasia location data, the 
accuracy of imaging modalities were assessed in terms of ability to correctly 
lateralize disease and also to identify the precise location (i.e. right/left, 




Information on the location of the diseased parathyroid gland(s), dimensions, 
weight and ultimate histological subtype (adenoma, atypical adenoma, 
hyperplasia or carcinoma) was obtained from pathology reports.  Tumour 
volume was calculated using the mathematical formula for the volume of an 




Continuous variables were not normally distributed (assessed by Shapiro-Wilk 
test) and are reported as median (inter-quartile range). Comparisons between 
groups were analysed by Mann-Whitney U test or Kruskal-Wallis test (multiple 
groups).  Categorical data were compared by Chi-square test.  Correlations were 
analysed by Spearman rank test.  Logistic regression analysis was employed to 
determine independent predictors of the presence of clinical features, recourse 
to neck imaging, failure of neck imaging and recourse to surgery.  Statistical 
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significance was accepted at p < 0.05.  All statistical analyses were performed on 




Characteristics of cohort 
 
The median age at diagnosis of PHPT was 68 years (IQR 58 – 77). The majority of 
patients (82.3%, n = 503) were female.  Full baseline characteristics are 
presented in table 1.    
22.7% (n = 139) presented with adjusted calcium greater than 0.25mM above 
the upper limit of normal (a level above which guidelines recommend surgery). 
29.3% (171/584) had a phosphate below the reference range at presentation.   
11.1% (n = 68) had a PTH within the reference range, 54.5% (n = 333) had PTH 
above normal but less than twice the upper limit of normal, and 34.4% (n = 210) 
had a PTH greater than twice the upper limit of normal.  Only 1 of 251 (0.4%) 
surgically cured patients had a PTH < 5 pM at initial diagnosis (and only 1.8% of 
the total cohort).    Vitamin D was available at baseline in 413 patients and was 
sufficient in 21.3% (n = 88), insufficient in 46.0% (n = 190) and deficient in 
32.7% (n = 135).   18.5% of patients had chronic kidney disease (CKD) stage 
three, 0.5% had CKD4 and the remainder had normal renal function, as 
determined by eGFR.   
Genetic testing was performed in 51 patients: MEN-1 (31 normal, 1 pathogenic 
mutation, 2 variants of uncertain significance); MEN-2 (22 normal, 0 pathogenic 
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mutations); CASR (10 normal, 1 pathogenic mutation) and CDC73 (12 normal, 1 





The most commonly reported symptoms at initial presentation were bone or 
joint pain, fatigue, polyuria, polydipsia, and constipation or abdominal pain 
(table 1).  Low mood, memory impairment and weakness were less commonly 
recorded at diagnosis.  28.9% (176/610) reported no symptoms consistent with 
PHPT. Fatigue (2.88  [2.81 – 3.01] vs. 2.84 mM [2.73 – 2.98], P = 0.002) and 
weakness (2.94 [2.86 – 3.09] vs. 2.84 mM [2.75 – 2.98], P = 0.002] were 
associated with higher peak calcium but not PTH, adjusted calcium or calcium at 
presentation.  Polydipsia was associated with higher adjusted calcium (2.77 
[2.64 – 2.92] vs. 2.72 mM [2.65 – 2.82], P = 0.041), higher peak calcium (2.92 
[2.81 – 3.06] vs. 2.84 [2.75 – 2.96], P < 0.001) and higher PTH (14.2 [10.8 – 21.1] 
vs. 12.0 pM [9.2 – 16.5], P = 0.002).  Similarly polyuria was associated with 
higher adjusted calcium (2.76 [2.67 – 2.91] vs. 2.72 [2.65 – 2.83], P = 0.020) and 
peak calcium [2.89 [2.80 – 3.06] vs. 2.84 mM [2.75 – 2.96], P = 0.005).  
Constipation or abdominal pain was associated with higher presenting calcium 
(2.77 [2.68 – 2.90] vs. 2.73 [2.66 – 2.83], P = 0.016) but not peak calcium, 
adjusted calcium or PTH.  Logistic regression analysis identified peak calcium 
(fatigue [OR 3.304, P = 0.028], polydipsia [OR 7.512, P = 0.012]) and PTH 
(polyuria [1.014, P = 0.045]) as being independently associated with symptoms; 
full analysis and logistic regression models are presented in section 1 of the 
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supplementary appendix.  Memory impairment, depression and bone/joint pain 




Previous bone fracture was present in 16.4% (n = 100) at presentation with no 
significant clinical or biochemical (including  PTH and calcium) associations 
observed (supplementary appendix section 2.A).  A history of nephrolithiasis 
was present in 10.0% at initial presentation (n = 61) and was associated with 
higher adjusted calcium (2.80 [2.69 – 2.92] vs. 2.72 mM [2.64 – 2.82], P = 0.002) 
and PTH (13.2 [10.3 – 22.0] vs. 12.1 [9.3 – 16.7], P = 0.043), although in logistic 
regression analysis, younger age (OR 0.974, P = 0.006) and male gender (OR 
1.972, P = 0.037), but not biochemical indices, were associated with the presence 
of renal stones at presentation (supplementary appendix 2.B).  Cardiovascular 
disease was present in 16.7% (n = 102) at diagnosis of PHPT and hypertension in 
43.5% (n = 266), neither were independently associated with biochemical 
indices of PHPT (supplementary appendix 2.C-D).   
 
19.5% (n = 119) of patients were on a thiazide diuretic (specifically, 
bendroflumethazide) at diagnosis with no independently significant differences 
in biochemistry between thiazide treated and non-thiazide treated patients 
(supplementary appendix 2.E).  Standard practice was to discontinue thiazide 
diuretics in all patients with PHPT. At 1 year follow up (n = 215 – no parathyroid 
surgery and 1 year data available) there was no significant difference in the 
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change in adjusted calcium: -0.01 [-0.11 - 0.06] in thiazide exposed vs. -0.04 mM 
[-0.11 – 0.04] with no previous thiazide, P = 0.514.    
 
Correlation analyses   
 
PTH was not correlated with age or BMI but was associated with adjusted 
calcium (R 0.350, P < 0.001), urinary CCCR (R 0.145, P < 0.05) and tumour 
volume (R 0.494, P < 0.001).  A weaker association existed between tumour 
volume and adjusted calcium (R 0.246, P < 0.001).  Vitamin D was only 
significantly inversely correlated with PTH (R -0.270, P < 0.001).  The full 
correlation matrix is presented in table 2. 
 
Discriminatory value of CCCR 
 
CCCR was measured in 220 patients (36.0%).  Urine CCCR did not differ 
significantly between individuals with vitamin D sufficiency (0.017 [0.009 – 
0.024], n = 45), insufficiency (0.016 [0.009 – 0.020], n = 72) and deficiency 
(0.015 [0.009 – 0.021], n = 50, P = 0.612) (Figure 1).  Similarly, urine CCCR did 
not significantly differ between spot urine samples (0.015 [0.010 – 0.023], n = 
104] and 24-hour urine collection samples (0.016 [0.010 – 0.023], n = 116, P 
=0.239).  CCCR was <0.01 in 18/99 (18.2%) surgically cured cases of PHPT and 
was <0.02 in 60/99 (60.6%).     
 
Neck imaging  
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64.8% (n = 396) of patients received at least one modality of neck imaging.  
Independent predictors of neck imaging in this cohort included younger age (OR 
0.912, P <0.001), higher adjusted calcium (OR 38.3, P < 0.001), lower phosphate 
(OR 0.05, P < 0.001), higher PTH (OR 1.03, P = 0.02) and presence of renal stones 
at presentation (OR 2.5, P = 0.046).  The presence of osteoporosis or previous 
fracture was not associated with the decision to request neck imaging (full 
results presented in supplementary appendix section 3.A).  
 
Neck ultrasound was performed in 61.2% of patients (n = 374), of whom an 
adenoma was reported as being identified in 66.0% (n = 247).  Failure to identify 
an adenoma on ultrasound was associated with older age (66 [60 – 77] vs. 62 
years [51 – 71], P < 0.001), lower peak calcium (2.86 [2.78 – 3.00] vs. 2.91 mM 
[2.82 – 3.05], P = 0.014), lower PTH (12.0 [8.7 – 16.6] vs. 14.0 pM [10.0 – 19.7], P 
= 0.006] and higher creatinine (72 [64 – 87] vs. 69μM [61 – 81], P = 0.022).  Age 
(OR 0.963, P < 0.001), PTH  (OR 1.027, P  = 0.043) and creatinine (OR 0.989, P = 
0.047), were all independently predictive in logistic regression analysis 
(presented in full in supplementary appendix section 3.B).  The relationship with 
age remained present when the analysis was limited to patients with subsequent 
surgical cure (OR 0.963, P < 0.001) and so does not represent misdiagnosis of 
PHPT.  Tumour volume and weight (at subsequent surgery) was not associated 
with the failure of ultrasound to detect an adenoma (supplementary appendix 
3.B).   
 
Where an adenoma was identified on ultrasound, the laterality was confirmed to 
be correct at surgery in 94.5% of cases (172/182).  The corresponding figure for 
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sestamibi uptake was 66.1% (76/115); for the CT component of SPECT CT this 
was 83.3% (35/42).  The number of 4DCT scans was substantially lower, but 
7/10 adenomas reported were on the correct side at surgery.  The full details of 
precise localisation (i.e. correct laterality and whether superior/inferior) are 
presented in table 3 for patients who had parathyroid surgery.  The proportion 
of imaging studies which identified an adenoma and how this related to non-
curative surgery are presented in table 4. 
 
Delayed diagnosis and treatment 
 
The interval between an elevated calcium and measurement of PTH was less 
than 1 year in 72.5% of patients (n = 443) but was between 1 – 5 years in 15.5% 
(n = 95) and greater than 5 years in 11.9% (n = 73).  Patients with a delayed 
diagnosis were younger (62 [51 – 60] vs. 67 years [57 – 66], P = 0.004) and had 
lower initial adjusted calcium concentration (2.64 [2.59 – 2.72] vs. 2.76 [2.59 – 
2.72], P < 0.001) but no difference in PTH (full results presented in 
supplementary appendix section 4).   
Where the diagnosis of PHPT was made within 1 year, 26.1% received surgery 
within 1 year, 18.9% between 1 and 5 years and 1.6% beyond 5 years (no 
surgery in 53.4%).  Where the diagnosis was made between 1 and 5 years, 31.2% 
received surgery within this timeframe and a further 7.5% received surgery 
beyond 5 years (no surgery in 61.3%).  Where the diagnosis was delayed beyond 
5 years, 38.3% received surgery (no surgery in 61.6%).   
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Features associated with having parathyroid surgery 
 
44.8% of our patients (n = 274) had parathyroid surgery.  Surgery was more 
likely in younger individuals (61 [50 – 70] vs. 74 years [66 – 81], P < 0.001), 
those with higher adjusted calcium (2.78 [2.68 – 2.92] vs. 2.70 mM [2.64 – 2.77], 
higher PTH (14.3 [10.0 – 20.2] vs. 11.4 pM [8.8 – 14.3], P < 0.001), where neck 
imaging identified an adenoma (OR 3.3, P < 0.001) and those with a history of 
nephrolithiasis (OR 1.80, P <0.001).  Osteoporosis was not associated with a 
higher likelihood of having had surgery (OR 0.89, P = 0.273), although after 
adjusting for age, there was a borderline association between osteoporosis and 
greater likelihood of surgery (OR 1.60, P = 0.057).  Logistic regression analysis 
confirmed identification of an adenoma on imaging (OR 10.7, P < 0.001), younger 
age (OR 0.92, P < 0.001), higher adjusted calcium (OR 15.3, P < 0.001) and 
history of nephrolithiasis (OR 3.1, P = 0.007) as being independently associated 
with the likelihood of surgery (full analysis presented in supplementary 
appendix section 5A-C).   
 
Predictors of non-curative surgery  
 
Surgery failed to cure PHPT in 8.4% of patients in our centre (23/274).  There 
were no significant differences in pre-operative clinical and biochemical 
parameters between those with curative and non-curative surgery 
(supplementary appendix section 6).  There was, however, an increased risk of 
non-curative surgery where more than one imaging modality was employed (OR 
2.42, P = 0.035) and a trend towards higher likelihood of non-curative surgery in 
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patients where US failed to identify an adenoma (OR 2.3, P = 0.052). Of the 23 
patients with non-curative surgery, 12 have had subsequent cure following 
reoperation.  One further patient was subsequently diagnosed with FHH.  
Ultimately only 11/273 (4.0%) of patients with PHPT and surgical intervention 
had persistent PHPT.   
 
 
Location of tumour and pathology 
 
Where a precise location was specified following surgery (n = 199), the right 
inferior position was the commonest adenoma site (40.7%, n = 81), followed by 
left inferior (33.2%, n = 66), left superior (9.0%, n = 18), right superior (8.0%, n 
= 16), multiple sites (7.0%, n = 14) and, finally, ectopic (2.0%, n = 4).  The full 
tumour location data is presented in section 7 of the supplementary appendix.  
The commonest pathological diagnosis was adenoma (79.8%, n = 205), followed 
by hyperplasia (12.8%, n = 33), carcinoma (4.3%, n = 11) and atypical adenoma 
(3.1%, n = 8).  Calculated tumour volume (R 0.494, P < 0.001), maximum tumour 
dimension (R 0.438, P < 0.001) and tumour weight (0.424, P < 0.001) were all 




We have reported the largest detailed, consecutive series of patients presenting 
to a secondary care endocrine service for evaluation of PHPT.  The results and 
conclusions drawn from this cohort are likely to be applicable to the majority of 
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endocrine centres across the United Kingdom and beyond.  Whilst susceptible to 
the typical criticisms of retrospective studies, the strength of this evaluation is its 




Asymptomatic PHPT is often a misnomer as most patients with PHPT describe 
symptoms which are at least consistent with hypercalcaemia.  Previous studies 
of symptoms frequency have suggested over 90% of patients report at least one 
symptom11,12.  These earlier studies were confined to patients awaiting 
parathyroid surgery and arguably represent the more severe end of the 
spectrum.  The corresponding figure in our study was 71.1%, although because 
we did not use a prospective data collection tool this may reflect under-
reporting.  Whilst fatigue was relatively common in our patients (23.8%), this 
was significantly lower than earlier reports (35 – 40%)11. In contrast, our 
reported prevalence of bone pain and polyuria were broadly consistent with 
previous estimates.  Consistent with earlier reports, fatigue and polyuria 
appeared to be the symptoms most closely associated with biochemical indices 




There is little doubt that PHPT is associated with an increased risk of 
nephrolithiasis.  Recent estimates of the lifetime risk of nephrolithiasis in the 
general population are 3 – 5% in women and 10 – 15% in men13.  In our cohort, 
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at presentation, 8.5% of women and 16.7% of men had a prior history of renal 
stones.  Interestingly, whilst univariate analysis demonstrated significantly 
higher adjusted calcium in those with renal stones, logistic regression identified 
only younger age and male gender as independent associations.  Indeed, in 
women first presenting over the age of 65, the prevalence of renal stones is close 
to the upper end of prevalence estimates for the general population (5.4%, 
16/295).  This suggests that aggressive case finding, with respect to 
nephrolithiasis, may be unnecessary in older women, although this would 
require validation in other populations.  That the presence of cardiovascular 
disease and hypertension were not associated with biochemical indices of PHPT 
is not surprising given the high prevalence of these conditions and the 
multifactorial contributions to their development14.  Presence of previous 
fracture was also unrelated to presenting biochemistry again probably 




As thiazide diuretics diminish urinary calcium excretion, received wisdom has 
been to discontinue this class of medication in patients diagnosed with PHPT, as 
this may reduce plasma calcium concentration.  If thiazides do have a significant 
impact on plasma calcium we would have expected to see greater reduction in 
calcium at one year after their cessation in our non-surgical patients on thiazide 
diuretics at diagnosis (thiazides were discontinued in all patients in this cohort).  
However, no significant difference was observed lending further evidence to the 
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contention9 that the diagnosis of PHPT should not lead to automatic 




Our demonstration that baseline urinary CCCR is less than 0.01 in 18.2% of 
patients with surgically confirmed PHPT calls into question the usefulness of this 
investigation in differentiating PHPT from FHH.  This frequency is broadly 
consistent with previous reports15,16,17. Yet the 4th international workshop on the 
diagnosis of PHPT8 suggests a greater than 95% chance of FHH when CCCR is 
<0.01.  This conclusion, which is commonplace in endocrine texts18, is based on 
positive predictive value estimates performed in samples highly enriched with 
FHH cases, despite this being a substantially less common condition than PHPT 
(prevalence estimated at 1 in 78,000 in Scotland)19.  PHPT remains by far the 
likeliest diagnosis in a hypercalcaemic patient with CCCR < 0.01.   
It is also frequently suggested that vitamin D status may complicate the 
interpretation of urinary CCCR results8. However, we found no difference in 
urinary CCCR between vitamin D deficient, insufficient and replete individuals 
and no correlation existed between indices of urinary calcium excretion and 
plasma vitamin D.  This lack of association is consistent with the observations in 
a small study of 35 PHPT patients20 and also with the lack of effect upon urinary 
calcium excretion observed following vitamin D replacement in patients with 
PHPT21.   
We did not observe any difference in CCCR between 24-hour samples and spot 
urine samples, although 24-hour collections may be indicated for a full 
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assessment of urinary calcium excretion in line with the current international 




Failure of imaging to identify an adenoma was independently associated with a 
lower likelihood of proceeding to surgery and, in those who had surgery, failure 
to cure PHPT was more likely where more than one imaging modality was 
required.  These facts strongly support the need for more effective second-line 
imaging modalities, as even 4DCT was associated with an appreciable failure 
rate.  This study cannot be regarded as a ‘head to head’ comparison of imaging 
modalities as only more complex cases were referred for imaging beyond neck 
ultrasound. As a proportion of all ultrasound scans with subsequent surgery, 
only 46.4% identified the precise location (including cases where no adenoma 
was identified) however 94.5% of scans where an adenoma was identified 
lateralized correctly.  This compares to precise localisation in 78% 22, 74%23, 
61%24 and 29%25 in previous studies. Differences in rates of adenoma 
identification between this cohort and others may reflect different population 
characteristics, as we identified older age and lower PTH to be independent 
predictors of failure to identify an adenoma.  Evidence is mixed with respect to 
whether 99mTc-sestamibi is a superior initial investigation22-25 compared to 
ultrasound. Little difference appears to exist between planar 99mTc-sestamibi 
compared to 99mTc-sestamibi-SPECT26, which supports our decision to consider 
these scans as a single entity in our analysis.  4DCT is reported to lateralise 
correctly in 88% of cases and provide precise localisation in 70%25.  Although 
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the number of 4DCT results in our cohort was low, it suggests this investigation 
does not perform this well in selected difficult cases where earlier imaging 
modalities have failed to identify abnormal parathyroid gland(s).  Recent 
experience with 18-fluorocholine PET/CT offers some hope that this modality 
may offer improved performance in difficult cases where conventional imaging 




We have confirmed the findings of earlier investigators that the majority of 
parathyroid adenomas (>70%) occur in glands in the inferior position28.  
Previous reports have offered conflicting evidence on the relationship between 
PTH at diagnosis and adenoma size29,30. However our series, which is the largest 
to address this question, shows an unequivocal relationship with respect to both 
calculated adenoma volume and weight.  The prevalence of parathyroid 
carcinoma (4.3%) was higher than is suggested elsewhere (<1% of cases of 
PHPT)31 but this may be a consequence of referral bias i.e. ‘milder’ PHPT in older 
patients is less likely to be referred to secondary care and our population is 
therefore enriched with more severe disease. Otherwise the mix of pathological 
diagnoses is broadly in accord with the previous literature1.  Non-curative 
surgery was most strongly associated with difficulties in identifying disease on 
neck imaging and this has been reported by other investigators previously32.  
Earlier reports also identified older age, higher calcium and lower PTH as risk 
factors for failed surgery33.  Whilst our study was perhaps underpowered to 
reproduce these findings, trends were consistent with this larger series.  Our 
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centre has not utilised intra-operative PTH assessment but this is a potentially 
attractive option, particularly in patients where risk factors for non-curative 




Over a quarter of patients in this cohort had a substantial delay between the first 
episode of hypercalcaemia and the diagnosis of PHPT, with 11.9% waiting over 5 
years before PTH was measured.  This is perhaps unsurprising given an earlier 
series where only 31% of hypercalcaemic patients had a PTH concentration 
assessed4.  Although it is difficult to quantify the potential harm inherent in 
delayed diagnosis, younger patients were more likely to belong to this category 
and 38% of those with greater than 5 year delay ultimately received surgery.  As 
well as exposure to symptoms and risk of classical PHPT complications, 
observational evidence associates elevated PTH with a greater risk of 
cardiovascular disease and mortality35.  Whilst we cannot infer causation from 
these observational data, it seems prudent to ensure timely diagnosis and 
expeditious referral for treatment in those where surgery is indicated.  Our data 
suggest the need for improved systems and greater education in helping non-




The insights gained from this cohort provide useful information on the most 
discriminant clinical features of PHPT and further reassurance that thiazide 
Page 22 of 36
Downloaded from Bioscientifica.com at 09/20/2018 02:10:28PM
via free access
diuretic use is safe in PHPT. This series also suggests additional caution is 
required in the interpretation of CCCR and perhaps greater recourse to genetic 
testing, particularly as the cost of this technology plummets.   With respect to 
imaging, we have demonstrated that neck ultrasound, when an enlarged 
parathyroid gland is positively identified, is highly accurate in lateralizing 
disease.  However, failure to identify an enlarged parathyroid, and the 
requirement for multiple imaging modalities, is a significant risk factor for non-
curative surgery. Improved and novel imaging modalities are required to 
minimise the risk of unsuccessful surgery.  Worryingly, it appears the delay in 
diagnosis of PHPT is unacceptably long in many patients, suggesting the need for 
better systems and better education for non-specialists to ensure prompt 
diagnosis and, where appropriate, treatment.   
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Figure 1:  Urine CCCR presented across vitamin D categories.  Horizontal line 
denotes 0.01 threshold (P = 0.612 between the three vitamin D categories). N/A 
not measured  
 
Figure 2:  Maximum tumour dimension (median +/- IQR) presented by PTH 
category at diagnosis (comparison across groups P < 0.001). 
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Table 1:  Summary of presenting features in patients with PHPT. 
 
 N  Reference range Median (IQR)  
Age at first high calcium  (years) 611  66.3 (56.4 – 64.9)  
Age at first PTH result (years) 611  68.0 (58.0 – 77.0) 
Interval from high calcium to PTH 
measurement (months) 
611  1 (0 – 18.5) 
Weight (kg) 448  73.3 (62.0 – 74.6) 
BMI (kg/m2) 445  27.8 (24.2 – 28.4) 
SIMD rank (out of 6976) 610  4347 (2337 – 6210) 
Gender 611  503 (82.3%) female  
108 (17.7%) male 
Fatigue at presentation 610  145/610  (23.8%) 
Weakness at presentation 610  29/610 (4.8%) 
Memory impairment at presentation 610  61/610 (10%) 
Depression at presentation 610  81/610 (13.4%)  
Polydipsia at presentation  610  91/610 (14.9%) 
Polyuria at presentation 610  95/610 (15.6%) 
Bone / joint pain at presentation  610  168/610 (27.5%) 
Previous fracture at presentation 611  100/611 (16.4%) 
Constipation / abdominal pain at 
presentation 
611  88/611 (14.4%) 
Thiazide diuretic at presentation 611  119/611 (19.5%) 
Previous/current lithium therapy 611  18/611 (2.9%) 
Renal stones at or prior to diagnosis 611  61/611 (10.0%) 
Cardiovascular disease at diagnosis 611  102/611 (16.7%) 
Calcium (mM) at diagnosis 611 2.1 – 2.6 2.73 (2.66 – 2.84) 
Adjusted calcium (mM) at diagnosis 611 2.1 – 2.6 2.72 (2.65 – 2.84) 
Peak calcium (mM) 611 2.1 – 2.6 2.85 (2.75 – 2.99) 
PTH at diagnosis (pM) 611 1.6 – 7.5  12.1 (9.3 – 17.2) 
Vitamin D (nM)  413 >50 31 (22 – 48) 
Phosphate at diagnosis (mM) 584 0.8 – 1.4 0.90 (0.77 – 1.01) 
Magnesium (mM)  243 0.7 – 1.0 0.84 (0.73 – 0.91) 
Creatinine (μM) 611 60 – 120  71 (63 – 87) 
Alkaline phosphatase (U/L) 611 40 – 125  94 (78 – 114) 
Urine calcium (mM) 334  3.6 (2.0 – 5.3) 
Urine calcium (mmol/24hrs) 216 <7.5 6.1 (3.8 – 9.0) 
Urine CCCR 220  0.0158 (0.0091 – 0.0213) 
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Table 2:  Correlations between clinical and biochemical parameters in patients with PHPT (n = 611 unless stated otherwise).  
Spearman correlation results above black boxes / P values below black boxes. 
 
 BMI  
(n = 445) 




(n = 584) 
PTH Vitamin D 
(n = 413) 
Creatinine Urine calcium 
per litre 
(n = 334) 
CCCR  




(n = 232) 
Tumour weight 
(n = 213) 
Tumour 
volume 
(n = 213) 
BMI  -0.106 0.034 -0.185 0.027 -0.008 0.105 0.135 -0.059 -0.104 -0.026 -0.053 
Age 0.026  0.024 0.106 0.047 -0.063 0.257 -0.239 -0.052 0.030 0.011 0.040 
Adjusted 
calcium 
0.468 0.557  -0.216 0.350 -0.019 0.026 0.137 0.125 0.254 0.230 0.246 
Phosphate <0.001 0.010 <0.001  -0.327 0.131 -0.052 -0.198 -0.044 -0.234 -0.256 -0.241 
PTH 0.576 0.242 <0.001 <0.001  -0.270 0.070 0.122 0.145 0.438 0.424 0.494 
Vitamin D 0.883 0.205 0.700 0.009 <0.001  0.035 -0.117 0.079 -0.003 -0.081 -0.056 
Creatinine 0.026 <0.001 0.526 0.207 0.083 0.475  -0.261 -0.055 0.169 0.236 0.185 
Urine 
calcium 
0.028 <0.001 0.012 <0.001 0.026 0.072 <0.001  0.506 0.151 0.146 0.160 




0.197 0.646 <0.001 <0.001 <0.001 0.972 0.010 0.067 0.006  0.786 0.848 
Tumour  
weight 
0.756 0.869 <0.001 <0.001 <0.001 0.380 <0.001 0.090 <0.001 <0.001  0.821 
Tumour 
volume 
0.524 0.563 <0.001 <0.001 <0.001 0.538 0.007 0.062 0.022 <0.001 <0.001  
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116 (46.4%) 59 (42.8%) 30 (66.7%) 7 (53.8%) 














0 (0.0%) 1 (0.72%) 0 (0.0%) 0 (0.0%) 
No adenoma at 
surgery 




7 (2.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
TOTAL 250 138 45 13 
 
Page 33 of 36
Downloaded from Bioscientifica.com at 09/20/2018 02:10:28PM
via free access
Table 4: Presence of enlarged parathyroid on imaging, whether surgery was performed and ultimate outcome of surgery by 
imaging modality and number of modalities employed. Where 99mTc-sestamibi SPECT CT was performed this is considered as 2 
modalities (CT and scintigraphy).  Planar 99mTc-sestamibi and 99mTc-sestamibi SPECT are reported as a single category. 
 
 1 modality 2 modalities 3 modalities 4 modalities Tumour on 
scan? 
Surgery done? Surgery failed? 




































   








   
Surgery failed? 7/140 (5.0%) 7/51 (13.7%) 7/75 (7.9%) 2/6 (33.3%)    
 










Figure 1:  Urine CCCR presented across vitamin D categories.  Horizontal line denotes 0.01 threshold (P = 
0.612 between the three vitamin D categories). N/A not measured  
 
264x125mm (96 x 96 DPI)  
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Figure 2:  Maximum tumour dimension (median +/- IQR) presented by PTH category at diagnosis 
(comparison across groups P < 0.001).  
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